Secoisolariciresinol Diglucoside (SDG) Isolated from Flaxseed, an Alternative to ACE Inhibitors in the Treatment of Hypertension

Abstract

Secoisolariciresionol diglucoside (SDG) is a plant lignan isolated from flaxseed and is phytoestrogen. SDG is a potent and long-acting hypotensive agent. Plant phytoestrogens have inhibitory effects on angiotensin-converting enzyme (ACE). The hypotensive effects of SDG, a phytoestrogen, may be mediated through inhibition of ACE. The objective of this study was to investigate if SDG-induced hypotension is mediated through inhibition of ACE. The Sprague Dawley male rats were anesthetized and trachea was cannulated. The right jugular vein was cannulated to administer the drug and the carotid artery was cannulated to record arterial pressures using PIOEZ-1 miniature model transducer (Becton, Dickinson and Company, Franklin Lakes, NJ) and Beckman dynograph (Beckman Instruments, Inc., Schiller Park, IL). The effects of angiotensin I (0.2 µg/kg, intravenously [IV]) in the absence and presence of SDG (10 mg/kg, IV), and SDG alone on systolic, diastolic, and mean arterial pressures were measured before and after 15, 30, and 60 minutes of drug administration. SDG decreased the systolic, diastolic, and mean arterial pressure by 37, 47, and 43%, respectively, at 15 minutes and 18.8, 21.2, and 20.3%, respectively, at 60 minutes. Angiotensin I increased the arterial pressure. SDG decreased angiotensin I-induced rise in the systolic, diastolic, and mean arterial pressures by 60, 58, and 51%, respectively, at 15 minutes and 48, 46, and 30%, respectively, at 60 minutes. The data suggest that SDG reduced the angiotensin I-induced rise in the arterial pressures and hence SDG is a potent ACE inhibitor.

Keywords

arterial pressures - angiotensin I - angiotensin-converting enzyme inhibitor - secoisolariciresinol diglucoside - flaxseed

• References

• 1 Oomah BD, Mazza G. Flaxseed proteins: a review. Food Chem 1993; 48 (2) 109-114
• 2 Hettiarachchy NS, Hareland GA, Ostenson A, Bladner-Shank G. Chemical composition of 11 flaxseed varieties grown in North Dakota. Proc Flax Institute 1990; 53: 36-50
• 3 Prasad K, Mantha SV, Muir AD, Westcott ND. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis 1998; 136 (2) 367-375
• 4 Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99 (10) 1355-1362
• 5 Westcott ND, Muir AD. Process for extracting lignans from flaxseed. US Patent No. 5705618, January 6, 1998
• 6 Obermeyer WR, Musser SM, Betz JM, Casey RE, Pohland AE, Page SW. Chemical studies of phytoestrogens and related compounds in dietary supplements: flax and chaparral. Proc Soc Exp Biol Med 1995; 208 (1) 6-12
• 7 Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6 (1) 7-13
• 8 Prasad K. Antihypertensive activity of secoisolariciresinol diglucoside (SDG) isolated from flaxseed: role of guanylate cyclase. Int J Angiol 2004; 13: 7-14
• 9 Nileeka Balsuriya BW, Vasantha Rupasinghe HP. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. Functional Foods Health Disease. 2011; 1 (5) 172-188
• 10 Shimakage A, Shinko M, Yamada S. ACE inhibitory substances derived from soy foods. J Biol Macromol 2012; 12 (3) 72-80
• 11 Gross DM, Sweet CS, Ulm EH , et al. Effect of N-[(S) – 1-carboxy-3-phenylpropyl] – L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressure response in vivo. J Pharmacol Exptl Ther. 1981; 216 (3) 552-557
• 12 Muirhead EF, Prewitt Jr RL, Brooks B, Brosius Jr WL. Antihypertensive action of the orally active converting enzyme inhibitor (SQ 14, 225) in spontaneously hypertensive rats. Circ Res 1978; 43 (Suppl. I): 153-159
• 13 Fregly MJ, Lockley OE, Simpson SE. Effect of the angiotensin-converting enzyme inhibitor, captopril, on development of renal hypertension in rats. Pharmacology 1981; 22 (5) 277-285
• 14 Zimmerman BG, Mommsen C, Kraft E. Renal vasodilatation caused by captopril in conscious normotensive and Goldblatt hypertensive dogs. Proc Soc Exp Biol Med 1980; 164 (4) 459-465
• 15 Alexander JC, Meyer JH. Comparison of captopril with placebo in the treatment of essential hypertension. In: Horovitz ZP, , ed. Angiotensin Converting Enzyme Inhibitors, Mechanisms of Action And Clinical Implications. Baltimore and Munich: Urban and Schwarzenberg; 1981: 379-392
• 16 Edgar L, Hogg A, Scott M , et al. ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method. Rev Recent Clin Trials 2011; 6 (1) 69-93
• 17 Canter D, Frank G. ACE inhibitors in the treatment of hypertension in the older patient. Eur Heart J 1990; 11 (Suppl D): 33-43
• 18 Feldman R. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X. Can J Cardiol 2000; 16 (Suppl E): 41E-44E
• 19 Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97 (14) 1411-1420